Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials

BACKGROUND: Patients undergoing chemotherapy are known to be at risk for infection from myelosuppression by cytotoxic agents (CTAs) or immunosuppressive effects from mTOR inhibitors. The infection risk of newly developed anticancer agents has not been fully evaluated. It remains unknown how T-cell a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:ESMO Open
Autors principals: Fujiwara, Yutaka, Kuchiba, Aya, Koyama, Takafumi, Machida, Ryunosuke, Shimomura, Akihiko, Kitano, Shigehisa, Shimizu, Toshio, Yamamoto, Noboru
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7174012/
https://ncbi.nlm.nih.gov/pubmed/32276948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000653
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars